Immitra Bio

Immitra Bio is pioneering a new class of in-vivo gene editing therapies designed to make genetic cures safe, scalable, and accessible. Our platform activates the body’s own “backup” genes to restore health from within—bypassing the need for risky bone marrow transplants or complex ex vivo procedures. By combining precision prime editing with advanced lipid nanoparticle delivery, we enable highly efficient, one-time edits directly inside the body. This approach overcomes key limitations of current gene therapy, which often struggles with safety, delivery, and mutation-specific constraints. Founded as an ETH Zürich spin-off, Immitra Bio unites deep expertise in genome engineering and translational biotech with a mission to transform gene editing into a practical, curative medicine platform. Our goal is to bring the next generation of in-vivo therapies to patients worldwide—safer, simpler, and built to scale.